Drug intelligence / Profile preview

99mTc-MAG3-Pep-1

Development stage
Unknown
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

99mTc-MAG3-Pep-1 is a radiolabeled peptide, composed of the synthetic peptide "Pep-1" conjugated to mercaptoacetyltriglycine (MAG3), which is then labeled with technetium-99m (99mTc). While 99mTc-MAG3 alone is a well-established renal radiopharmaceutical primarily used for renal scintigraphy and assessment of renal function, the addition of a "Pep-1" moiety indicates this is a targeted imaging agent, where Pep-1 may serve as a vector or ligand for specific molecular targets (such as cancer biomarkers or receptors), enabling targeted single photon emission computed tomography (SPECT) imaging. This agent works through delivery of a gamma-emitting 99mTc isotope to sites of Pep-1 binding, allowing for noninvasive molecular imaging of tissues expressing the Pep-1 target. Mechanisms and specific indications depend on the "Pep-1" peptide’s target, but such radiopharmaceuticals are typically developed for molecular imaging in oncology, tissue targeting, or receptor mapping.

02

Targets

IL13RA2 (Interleukin-13 receptor subunit alpha 2)

Beyond the preview

Go deeper on 99mTc-MAG3-Pep-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-MAG3-Pep-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call